Monica Vetter, PhD

Chair, Department of Neurobiology and Anatomy

Research Interests

  • Developmental Neurobiology
  • Retinal Degeneration and Cell Biology

Languages

  • English

Academic Information

  • Departments: Neurobiology and Anatomy - Professor, Ophthalmology/Visual Sciences - Adjunct Professor

Academic Office Information

  • 801-581-4984
  • Biomedical Polymers Research Bldg
    Neurobiology and Anatomy
    20 S 2030 E, Room: 320B
    Salt Lake City, UT 84112

Email: monica.vetter@neuro.utah.edu

Academic Bio

My laboratory is focused on understanding the molecular pathways controlling neural development and degeneration in the retina. The retina is of critical importance since disorders of eye development can lead to congenital blindness, while degeneration of retinal neurons can cause progressive blindness at later ages.

Retinal development:   In the developing retina we are studying how eye tissues are patterned and how retinal progenitors are directed to adopt specific retina cell fates. Our goal is to define the sequence of gene expression that governs neural differentiation in the retina, and understand how extrinsic signaling pathways modulate gene expression or function. We began by addressing how proneural transcription factors control retinal neuron differentiation, and how they contribute to the ordered sequence of retinal histogenesis. We have found that both the expression and activity of proneural factors are controlled multiple signaling pathways, thus regulating the timing of retinal neuron differentiation. We are now examining how epigenetic mechanisms, particularly histone modifications, regulate the proliferation and differentiation of progenitor cells in the retina. We have determined that the PRC2 repressive complex is required to maintain transcriptional integrity of retinal progenitors, and preserve their capacity for proliferation in both mouse and Xenopus. Ezh2, a key member of this complex, is required to coordinate the timing of differentiation and generate the appropriate complement of retinal cell types. Our transcriptome analysis also shows that Ezh2 may have a core function in repressing the expression of potent developmental regulators and cell cycle genes regardless of tissue lineage. Ultimately, the goal is to reveal general principles governing the development of neural stem cells and progenitors, which may inform efforts to harness these cells for the treatment of disease and injury of the nervous system.

Retinal ganglion cell degeneration:   We are probing the mechanisms underlying glaucoma, a neurodegenerative disease of the retina that is characterized by progressive loss of retinal ganglion cells leading to blindness. As part of the Catalyst for a Cure research consortium, we identified early events involved in the decline of retinal ganglion cells (RGCs), such as genetic deprogramming of RGCs, and recruitment of glia, including microglia, Müller glia and astrocytes. It is now clear that glaucoma bears the hallmark features of a classic, progressive neurodegenerative disease with common cellular and molecular changes found in other neurodegenerative diseases. Using a mouse model for chronic glaucoma, we have demonstrated significant recruitment and activation of microglia, which are the resident immune surveillance cells of the CNS, at very early stages of the disease. We have established methods for live monitoring of microglia during early disease progression, and demonstrated that these early microglial changes at the optic nerve head are reliable predictors of future optic nerve neurodegeneration severity. We are directly testing the role of microglia in neuronal decline, and have showed that reducing microglia activation is neuroprotective. We are now targeting molecular pathways involved in the recruitment and activation of these cells. Our ultimate goal is to identify key molecular pathways that can be targeted to slow or prevent blindness in glaucoma.

Education History

Type School Degree
Postdoctoral Fellowship University of California
Neuroscience
Postdoctoral Fellow
Doctoral Training University of California
Neuroscience
Ph.D.

Selected Publications

Journal Article

  1. Bosco A, Romero CO, Breen KT, Chagovetz AA, Steele MR, Ambati BK, Vetter ML (2015). Neurodegeneration severity can be predicted from early microglia alterations monitored in vivo in a mouse model of chronic glaucoma. Dis Model Mech, 8(5), 443-55.
  2. Zhang J, Taylor RJ, La Torre A, Wilken MS, Cox KE, Reh TA, Vetter ML (2015). Ezh2 maintains retinal progenitor proliferation, transcriptional integrity, and the timing of late differentiation. Dev Biol, 403(2), 128-38.
  3. Bosco A, Romero CO, Ambati BK, Vetter ML (2015). In vivo dynamics of retinal microglial activation during neurodegeneration: confocal ophthalmoscopic imaging and cell morphometry in mouse glaucoma. J Vis Exp, (99), e52731.
  4. Willardsen M, Hutcheson DA, Moore KB, Vetter ML (2014). The ETS transcription factor Etv1 mediates FGF signaling to initiate proneural gene expression during Xenopus laevis retinal development. Mech Dev, 131, 57-67.
  5. Aldiri I, Moore KB, Hutcheson DA, Zhang J, Vetter ML (2013). Polycomb repressive complex PRC2 regulates Xenopus retina development downstream of Wnt/beta-catenin signaling. Development, 140(14), 2867-78.
  6. Bosco A, Crish SD, Steele MR, Romero CO, Inman DM, Horner PJ, Calkins DJ, Vetter ML (2012). Early reduction of microglia activation by irradiation in a model of chronic glaucoma. PLoS One, 7(8), e43602.
  7. Bosco A, Steele MR, Vetter ML (2011). Early microglia activation in a mouse model of chronic glaucoma. J Comp Neurol, 519(4), 599-620.
  8. Green YS, Vetter ML (2011). EBF factors drive expression of multiple classes of target genes governing neuronal development. Neural Dev, 6, 19.
  9. Masserdotti G, Badaloni A, Green YS, Croci L, Barili V, Bergamini G, Vetter ML, Consalez GG (2010). ZFP423 coordinates Notch and bone morphogenetic protein signaling, selectively up-regulating Hes5 gene expression. J Biol Chem, 285(40), 30814-24.
  10. Willardsen MI, Suli A, Pan Y, Marsh-Armstrong N, Chien CB, El-Hodiri H, Brown NL, Moore KB, Vetter ML (2009). Temporal regulation of Ath5 gene expression during eye development. Dev Biol, 326(2), 471-81.
  11. Riesenberg AN, Le TT, Willardsen MI, Blackburn DC, Vetter ML, Brown NL (2009). Pax6 regulation of Math5 during mouse retinal neurogenesis. Genesis, 47(3), 175-87.
  12. Agathocleous M, Iordanova I, Willardsen MI, Xue XY, Vetter ML, Harris WA, Moore KB (2009). A directional Wnt/beta-catenin-Sox2-proneural pathway regulates the transition from proliferation to differentiation in the Xenopus retina. Development, 136(19), 3289-99.
  13. Aldiri I, Vetter ML (2009). Characterization of the expression pattern of the PRC2 core subunit Suz12 during embryonic development of Xenopus laevis. Dev Dyn, 238(12), 3185-92.
  14. Soto I, Oglesby E, Buckingham BP, Son JL, Roberson ED, Steele MR, Inman DM, Vetter ML, Horner PJ, Marsh-Armstrong N (2008). Retinal ganglion cells downregulate gene expression and lose their axons within the optic nerve head in a mouse glaucoma model. J Neurosci, 28(2), 548-61.
  15. Buckingham BP, Inman DM, Lambert W, Oglesby E, Calkins DJ, Steele MR, Vetter ML, Marsh-Armstrong N, Horner PJ (2008). Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci, 28(11), 2735-44.
  16. Bosco A, Inman DM, Steele MR, Wu G, Soto I, Marsh-Armstrong N, Hubbard WC, Calkins DJ, Horner PJ, Vetter ML (2008). Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci, 49(4), 1437-46.

Review

  1. Aldiri I, Vetter ML (2012). PRC2 during vertebrate organogenesis: a complex in transition. [Review]. Dev Biol, 367(2), 91-9.